glp 1 insulin secretion Science Behind GIP and Glucagon Receptor Agonists for Obesity Research | News & Announcements GLP-1 receptor activated insulin secretion

10.1210/js.2017-00426 72

However, the landmark SURMOUNT-5 trial (published in mid-2025), which compared the two medications head-to-head, clarified the clinical reality: Total Weight Loss: Tirzepatide drives significantly greater total weight loss (averaging over 20%) compared to semaglutide (averaging roughly 14%)

also demonstrated that the compound did not illicit an increase in blood pressure or heart rate in DIO NHPs at the efficacious dose of 0.5 mg/kg/24 h SC infusion over positive control LY2112688, further suggesting cardiac liabilities to be molecule specific (95)

With regards to specific outcomes such as HF, there has been heterogeneity in the results with both GLP-1RAs and DPP-4i

Healthy Meal Options: Explore local eateries offering healthy choices